Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.
Gross EE, Li M, Yin M, Orcutt D, Hussey D, Trott E, Holt SK, Dwyer ER, Kramer J, Oliva K, Gore JL, Schade GR, Lin DW, Tykodi SS, Hall ET, Thompson JA, Parikh A, Yang Y, Collier KA, Miah A, Mori-Vogt S, Hinkley M, Mortazavi A, Monk P, Folefac E, Clinton SK, Psutka SP. Gross EE, et al. Among authors: orcutt d. Urol Oncol. 2023 Jan;41(1):51.e25-51.e31. doi: 10.1016/j.urolonc.2022.08.013. Epub 2022 Oct 26. Urol Oncol. 2023. PMID: 36441070 Free PMC article.
Changes in skeletal muscle and adipose tissue during cytotoxic chemotherapy for testicular germ cell carcinoma and associations with adverse events.
Phuong A, Marquardt JP, O'Malley R, Holt SK, Laidlaw G, Eagle Z, Ngo S, Orcutt D, Schade GR, Lin DW, Schweizer MT, Yezefski T, Yu EY, Montgomery B, Grivas P, Fintelmann FJ, Psutka SP. Phuong A, et al. Among authors: orcutt d. Urol Oncol. 2022 Oct;40(10):456.e19-456.e30. doi: 10.1016/j.urolonc.2022.07.013. Epub 2022 Aug 23. Urol Oncol. 2022. PMID: 36028450
Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma.
Kwok C, Khorasanchi A, Psutka SP, Hinkley M, Dason S, Sundi D, Yang Y, Yang Y, Verschraegen C, Gross EE, Orcutt D, Yin M. Kwok C, et al. Among authors: orcutt d. Front Oncol. 2023 Jul 27;13:1231831. doi: 10.3389/fonc.2023.1231831. eCollection 2023. Front Oncol. 2023. PMID: 37576889 Free PMC article.
22 results